Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Oklahoma: - Cancer Centers of Southwest Oklahoma Research — Lawton, Oklahoma
- University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 3 Recruiting Industry
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Sponsor: Clarity Pharmaceuticals Ltd
NCT ID: NCT06056830
Sites in Oklahoma: - Urologic Specialists — Tulsa, Oklahoma
Phase 3 Recruiting Network
The purpose of this study is to compare the effects, good and/or bad of two treatment methods on subjects and their cancer. Proton beam radiation therapy is one of the treatments for men with prostate cancer who have localized disease. The…
Sponsor: Proton Collaborative Group
NCT ID: NCT01492972
Sites in Oklahoma: - Oklahoma Proton Center — Oklahoma City, Oklahoma
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in Oklahoma: - Cancer Centers of Southwest Oklahoma Research — Lawton, Oklahoma
- University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
- Mercy Hospital Oklahoma City — Oklahoma City, Oklahoma
- Oklahoma Cancer Specialists and Research Institute-Tulsa — Tulsa, Oklahoma
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial studies the best dose of M3814 when given together with radium-223 dichloride or with radium-223 dichloride and avelumab and to see how well they work in treating patients with castrate-resistant prostate cancer that …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04071236
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Oklahoma: - University of Oklahoma — Oklahoma City, Oklahoma
Phase 2 Recruiting NIH
This phase II trial studies if talazoparib works in patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and has mutation(s) in deoxyribonucleic acid (…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04550494
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 1 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) a…
Sponsor: Pfizer
NCT ID: NCT03460977
Sites in Oklahoma: - OU Health University of Oklahoma Medical Center — Oklahoma City, Oklahoma
- Stephenson Cancer Center (chemo location) — Oklahoma City, Oklahoma
Phase 1 Recruiting Industry
This is a first-in-human (FIH), multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as pharmacokinetics (PK) and pharmacodynamics of XL309 (previously ISM3091) administered…
Sponsor: Exelixis
NCT ID: NCT05932862
Sites in Oklahoma: - Exelixis Clinical Site #13 — Oklahoma City, Oklahoma
Phase 1 Recruiting Industry
The goal of study： The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug. The study team will make sure it is safe and tolerated before enrolling…
Sponsor: Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
NCT ID: NCT06751329
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 1 Recruiting Academic/Other
The goal of this clinical trial is to test how effective and safe it is to use a combination of two medications, relugolix and enzalutamide, in patients with advanced prostate cancer. We want to see if this combination can help improve the…
Sponsor: University of Oklahoma
NCT ID: NCT06130995
Sites in Oklahoma: - Stephenson Cancer Center at OU Health, University of Oklahoma Health Sciences Center (SCC-OUHSC) — Oklahoma City, Oklahoma
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Oklahoma: - Mercy Hospital Oklahoma City — Oklahoma City, Oklahoma
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Oklahoma: - Massive Bio SYNERGY-AI site — Tulsa, Oklahoma
NA Recruiting NIH
The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for mult…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06995898
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
NA Recruiting Industry
To assess the post-market clinical outcomes of the Axonics SNM System for treatment of overactive bladder in male patients.
Sponsor: Axonics, Inc.
NCT ID: NCT06511141
Sites in Oklahoma: - Utica Park Urology — Tulsa, Oklahoma
Recruiting Academic/Other
The purpose of this clinical trial is to evaluate radiation therapy (RT) completion rates among underrepresented cancer populations using qualitative measurements. Additionally, the study aims to assess the impact of patient navigators on …
Sponsor: University of Oklahoma
NCT ID: NCT07014618
Sites in Oklahoma: - OU Health Stephenson Cancer Center — Oklahoma City, Oklahoma